A counterfeit version of the injectable cancer drug bevacizumab that may contain no active ingredient has been distributed to clinics in the United States, according to a US Food and Drug Administration (FDA) alert to physicians. The incident is the latest in a string of cases in which foreign drug distributors have sold counterfeit medications to US medical practices.
According to the warning (http://tinyurl.com/ael9nwu), a US company calling itself Medical Device King (also known as Pharmalogical) distributed 2 batches of a counterfeit version of bevacizumab labeled as Altuzan. The counterfeits were labeled as Altuzan, 400 mg/16 mL, and had batch numbers B6022B01 (which bear an expiration date of November 2013) and B6024B01 (with an expiration date of February 2013).
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.